Metrics as of 10/17/2026, 07:43 AM (Berlin time), refresh in progress.
Halozyme Therapeutics Stock
Halozyme Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Helen I. Torley
- Employees
- 423
- Market cap
- $13.8 B
- IPO
- 16/03/2004
Halozyme Therapeutics, Inc. is a healthcare biotechnology company headquartered in San Diego, USA. Founded in 1998, the company operates its proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme. This technology significantly enhances the subcutaneous…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Halozyme Therapeutics stock: price history
1D
+0.3%
1W
+10.3%
1M
+12.4%
6M
+75.8%
YTD
+81.0%
1Y
+82.2%
2Y
+127.9%
5Y
+222.7%
10Y
+1,111.1%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~1% weaker price swings than usual
Halozyme Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
2 more assignments (Enabler/Second row) Pro-only.
Halozyme Therapeutics is a biopharmaceutical company that leverages its specialized ENHANZE technology to improve the subcutaneous delivery of medications. The core business model is primarily based on licensing its proprietary platform as well as the sale of pharmaceutical products and enzyme components. A significant portion of revenues is generated through royalty payments that partner companies make for utilizing the patented technology. Additionally, the company generates revenues through the direct sale of medications such as Hylenex, as well as through milestone payments and upfront fees as part of collaborations with major pharmaceutical companies. The platform enables manufacturers of poorly soluble biologics to simplify drug delivery for patients through subcutaneous injections.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- Low
- Customer concentration
- Unknown
Suppliers & customers in our universe
Pfizer Inc.Description
Eli Lilly and CompanyDescription
Bristol-Myers Squibb CompanyDescription
AbbVie Inc.DescriptionAsk the agents about Halozyme Therapeutics
Analyst assessment of Halozyme Therapeutics
PRICE TARGET LOW
US$90.00
CONSENSUS
US$110.00
MEDIAN
US$107.50
PRICE TARGET HIGH
US$130.00
0
STRONG BUY
18
BUY
8
HOLD
1
SELL
0
STRONG SELL
27
TOTAL · Buy
As of: 13/10/2026
Halozyme Therapeutics stock metrics
P/E
34.61
P/B
99.54
EV/EBITDA
22.01
RETURN ON EQUITY
160.2%
NET MARGIN
47.8%
DEBT/EQUITY
14.95
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.9%
FLOAT SHARES
112,270,065
AVG. DAILY VOLUME (30D)
2,429,243
Insider transactions (SEC)
Torley Helen
Torley Helen
Torley Helen
Torley Helen
Torley Helen
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.3%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Halozyme Therapeutics stock
What does Halozyme Therapeutics do?
Halozyme Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Helen I. Torley, the company employs around 423 people.
The IPO was on 16/03/2004; the stock trades on NASDAQ under the ticker HALO.
What do analysts say about Halozyme Therapeutics stock?
27 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$110.00, ranging from US$90.00 to US$130.00, with a median of US$107.50.
This is an external assessment, not a statement by Market Jury.
When does Halozyme Therapeutics report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly -1% stronger than usual.
Does Halozyme Therapeutics pay a dividend?
No, Halozyme Therapeutics currently does not pay a dividend.
Which stocks are comparable to Halozyme Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Halozyme Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Halozyme Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.